stockrowNovo Nordisk A/S
NVO Healthcare Drug Manufacturers General
Novo Nordisk A/S’s revenue for fiscal 2025 (year ended December 2025) was $46.8 billion, up 11.1% from fiscal 2024.
- Revenue
- +4.47%
- EPS
- −18.7%
- Free cash flow
- +71.6%
- Total debt
- +44.4%
Quarter to June 2026, against a year earlier
Follow NVO
Alert me
Novo Nordisk A/S (NVO) Net income
Novo Nordisk A/S's net income for fiscal 2025 was $15.5B, up 5.91% from $14.6B in fiscal 2024. Over the twelve months to 30 June 2026 it was $17.9B. Over the past ten years it has ranged from $5.2B (fiscal 2015) to $15.5B (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 6 consecutive fiscal years. Novo Nordisk A/S ranks 2nd of 21 Drug Manufacturers General companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $15.5B | 5.91% |
| FY2024 | $14.6B | 20.51% |
| FY2023 | $12.2B | 54.54% |
| FY2022 | $7.9B | 3.48% |
| FY2021 | $7.6B | 17.70% |
| FY2020 | $6.5B | 10.56% |
| FY2019 | $5.8B | (1.14%) |
| FY2018 | $5.9B | 1.97% |
| FY2017 | $5.8B | 2.77% |
| FY2016 | $5.6B | 8.65% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $3.2B | (57.69%) |
| Mar 2026 | $7.6B | 106.72% |
| Dec 2025 | $3.7B | 8.74% |
| Sep 2025 | $3.4B | (22.24%) |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| NVO Novo Nordisk A/S | $17.9B |
| AZN AstraZeneca PLC compare | $13.3B |
| NVS Novartis AG compare | $10.0B |
| AMGN Amgen Inc. compare | $9.4B |
| BMY Bristol Myers Squibb Company compare | $9.2B |
| GSK GSK PLC Sponsored ADR compare | $6.3B |
| SNY Sanofi compare | $4.5B |
| PFE Pfizer Inc. compare | $4.1B |
| GILD Gilead Sciences, Inc. compare | −$3.9B |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on NVO
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement